A New Research Study Aims to Improve Future Care for People with Moderate-to-Severe Eczema

Eczema, also known as atopic dermatitis (AD), is far more than a skin condition — it’s a daily struggle. The itching, irritation, and inflammation can interfere with sleep, self-esteem, and quality of life. For many, managing eczema is a lifelong journey that involves constant vigilance and trial-and-error treatments.

To help improve care for people living with moderate-to-severe eczema, researchers are conducting a new clinical study — the COMPASS 2-AD Study — designed to evaluate the safety and effectiveness of an investigational medication called BFB759.

About the Study

The COMPASS 2-AD study is investigating a potential new treatment for adults with moderate-to-severe atopic dermatitis. Participants will receive an injection under the skin (subcutaneous) every two weeks for 30 weeks.

This study includes three groups, and if you qualify, you’ll be randomly assigned to one of them — much like drawing numbers from a hat. Every participant will receive both the study drug and a placebo, but the dose and order will vary depending on the group you’re assigned to.

What You’ll Receive

• All study medication, examinations, and medical care related to the study will be provided at no cost.

• Compensation for your time and travel may be available.

• You’ll work closely with medical professionals who specialize in dermatology and eczema care.

Who Can Participate?

You may qualify if you:
✅ Are between 18 and 75 years old
✅ Have lived with moderate-to-severe atopic dermatitis for at least one year

There is no cost to participate, and you can help researchers understand how this investigational treatment could benefit people living with eczema worldwide.

Study Schedule and Procedures

• Visits: 22

• Duration: Up to 40 weeks total (including a 30-day screening period, 30 weeks of treatment, and a 6-week follow-up)

• Procedures:

  • Electrocardiogram (ECG)

  • Blood draws and urine samples

  • Medical physical exams

  • Medical photographs of skin lesions

  • Quality of life and itch severity questionnaires

  • Daily diary entries to track symptoms

Each visit may last 2–3 hours, depending on the procedures performed.

Why Participate?

By joining this study, you’ll:

• Contribute to groundbreaking research that could improve future eczema treatments.

• Gain access to expert medical care and monitoring.

• Potentially benefit from a promising investigational therapy designed to reduce symptoms and improve quality of life.

Study Snapshot

Ready to Learn More or Join the Study?

If you or someone you know has been living with eczema, this is your chance to make a difference.
Tap below to explore your eligibility and get started:

Explore the Study
or visit Clinago.life for more information.

Eczema doesn’t just affect skin — it affects life.
Help shape the future of eczema care by joining the COMPASS 2-AD study today.

FOLLOW PMN:

Link

Link AI Tools & Funding:

Link Earn Free TON Coins & USDT:

Link

Link